Most recent update: Friday, December 6, 2019 - 09:44

Bariatric News - Cookies & privacy policy

You are here


Positive study results for Obalon Balloon Navigation Device

Data highlight convenience, efficiency, and safety of Obalon’s proprietary Navigation and Touch Dispenser systems to achieve reliable balloon administration without the use of x-ray

Obalon Therapeutics announced that substantial clinical data from a study conducted with 14 clinical sites was presented at Obesity Weekend in Chicago by the study co-primary investigator, Dr Michael V Seger, Bariatric Surgeon at Bariatric Medical Institute (San Antonio, TX). The study included 397 balloon administration assessments from 155 patients with Dr Rachel L Moore, Bariatric Surgeon at Surgical Specialists of Louisiana (Metairie, LA) as the study’s co-primary investigator.

The co-primary endpoints of the Continuous Obalon Balloon Administration Location Tracking (COBALT) Study were met, with 100% correct decision-making for administering and inflating the Obalon Balloon System using the Navigation device instead of X-ray imaging. The study data also demonstrated 100% agreement between the Navigation System assessments and x-ray images collected but not used to make any decision to initiate inflation. There were no serious adverse events observed in the study and the overall adverse event rate was 3.9% with none of the events relating to the Navigation System or Touch Dispenser.

“These results suggest that the Navigation device can be used to safely and accurately administer Obalon Balloons without the use of radiography,” said Seger. “Prior studies support the ability to achieve safe and effective weight loss with the Obalon Balloon System, and the use of Navigation can remove a key barrier to balloon administration when X-ray imaging is not accessible.”

The Obalon Navigation System provides treating physicians with the ability to place the Obalon Balloon without having to incur the costs and inconvenience of utilizing x-ray imaging. The Obalon Navigation System is a portable, easy to use, non-invasive, radiation free, self-contained imaging system that is FDA approved for dynamic tracking of the Obalon Balloon during balloon administration.

“These data demonstrate the robustness of our Navigation System, which like our gastric balloon, continues to perform well in clinical studies and in commercial use,” said Amy VandenBerg, Chief Clinical and Regulatory Officer of Obalon. “We remain dedicated to improving the performance, usability and economics of the Obalon Balloon System and making this safe and effective technology more readily available to individuals with a BMI between 30 to 40 who are ready to lose weight and improve their overall health.”

Want more stories like this? Subscribe to Bariatric News!

Bariatric News
Keep up to date! Get the latest news in your inbox. NOTE: Bariatric News WILL NOT pass on your details to 3rd parties. However, you may receive ‘marketing emails’ sent by us on behalf of 3rd parties.